Peptron's animal half-life lead: competitors' is longer, and evidence for once-monthly human weight loss remains unclear
Predicted impact: Medium
Report questions drug half-life edge and monthly dosing evidence; follows earlier critical reports.
Peptron펩트론
087010 · KOSDAQ · ₩087010 · 펩트론
₩92,300▼ ₩4,900 (5.04%)End-of-day · Oct 30, 2026 · End-of-day prices.
[MK Signal] Peptron Rises on Global Expectations for SmartDepot Technology; 11.26% Gain Since MK Signal Recommendation
Predicted impact: Low
Media stock-pick recommendation performance; no company-specific new fact.
Peptron receives ₩1B instead of ₩4B after Yuhan terminates ₩4B technology transfer contract
Predicted impact: Medium
Yuhan terminates ₩4B tech transfer contract; Peptron receives ₩1B, about 0.04% of market value.
After clinical trial rejection and no word on technology transfer, Olix rides a rollercoaster amid Peptron shock
Predicted impact: Low
Clinical trial rejection and unannounced technology transfer; vague, no size given, small relative to news flow.
[Exclusive] Peptron, which had touted monthly dosing at most every 3 months, patent efficacy tests run up to 2 weeks apart
Predicted impact: Medium· Actual: +9.9% vs sector, volume 1.0× normal (5 trading days)
Report questions patent evidence behind dosing claims; market value is about 350x last year's revenue.
Also known as: Peptron / 펩트론 / 087010 / KRX:087010
Source: KRX statistical information